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The Proinsulin C-peptide Discovery, Structural Aspects and Role(s)
DONALD F. STENIER
University ofChicago, Chicago, IL
The C-peptide, which consists of the connecting segment of proinsulin minus the basic resides at each end, is a
product of proinsulin processing that is stored and cosecreted with insulin in essentially equimolar amounts
from the beta cell. It has been isolated from the pancreas of man and a number of other species and studies of its
secretion and metabolic clearance have established that it is a valuable and reliable indicator of beta-cell secreto-
ry function in normal and diabetic subjects. Unlike insulin, which is rapidly removed from the circulation by
receptor binding, the C-peptide has a prolonged half-life without significant tissue sequestration. In mammals
the C-peptide ranges in length from 26-31 residues, has a 15-fold greater rate of mutation acceptance than insulin
and is cleaved internally prior to secretion in some species, i.e., the dog, fox and others. It has a somewhat
restricted composition, notable for the absence of aromatic residues, and usually contains four or five acidic
residues, which offset the four basic amino acids at the cleavage sites thus maintaining a very similar isoelectric
point in proinsulin to that of insulin. The foremost biosynthetic role of the C-peptide clearly is to serve as a flexi-
ble linker between the insulin B andA chains so as to facilitate the proper folding of the peptide chain and disul-
fide bond formation. The C-peptide does this mainly by converting the bimolecular reaction of chain
combination to a more efficient monomolecular reaction, but this function can also be accomplished by much
shorter or even totally deleted connecting segments. The strong conservation of the length of the C-peptide in
evolution, however, is consistent with the requirement for its efficient excision from proinsulin during its conver-
sion to insulin; experiments with truncated C-peptides show marked reductions in conversion efficiency. Opti-
mal binding of proinsulin to the prohormone convertases for cleavage imposes significant constraints on the
length and.properties of the C-peptide, as will be discussed. Moreover, the C-peptide may play a role in sorting
and must be compatible with other constituents of the secretory granule in which it is stored, e.g., insulin, islet
amyloid peptide and others. In addition to these constraints, the mammalian C-peptides may have acquired
some additional beneficial functions that complement insulin action.
*Theme: "C-peptide: Has its time come? From mechanism of action to its use in diabetes".
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Overview of C-peptide Developments During the Last 10 Years
JOHNWAHREN
Section of Clinical Physiology, Department of Surgical Sciences,
Karolinska Institute, SE 171 77 Stockholm, Sweden
The observation in 1992 that C-peptide in physiological concentrations can correct glomerular hyperfiltration
and increase renal blood flow in patients with type 1 diabetes [11 became the starting point for continued studies
of C-peptide physiology in Stockholm These findings sub-sequently led to more detailed studies of renal func-
tion in diabetes, evaluation of C-peptide-blood flow interactions, studies of C-peptide’s cellular interactions and
signal transduction, and investigations of C-peptide and nerve function in diabetes.
The initially observed C-peptide effect on renal function has been confirmed and extended in both experimen-
tal studies in streptocotozin-diabetic (STZ) rats and type 1 diabetes patients. Thus, C-peptide replacement for
periods of two weeks to three months in animals and patients with early nephropathy results in diminished
glomerular hyperfiltration and reduced urinary albumin excretion. [2-4] The effect of C-peptide on blood flow has
been further examined using the forearm model in type 1 diabetes patients. A significant increase in forearm
blood flow is observed during i.v., infusion of C-peptide in the resting state. [51 Likewise, infusion of C-peptide
during rhythmic forearm exercise results in a marked increase in both blood flow and oxygen uptake. [6] The lat-
ter finding prompted an evaluation of C-peptide’s possible influence on Na+, K+-ATPase. It could be shown that
C-peptide has the capacity to stimulate renal tubular cell Na+, K+-ATPase activity in a concentration-dependent
manner, probably by activating a receptor coupled to a pertussis-toxin sensitive G-protein with subsequent acti-
2+ [71 vation of Ca -dependent intracellular signaling pathways. It could also be demonstrated in endothelial cells
that the C-peptide-induced rise in intracellular Ca2 + stimulates endothelial nitric oxide synthase activity and
causes release of NO, [81 thereby helping to explain the effects of C-peptide on blood flow.
It has been suggested that C-peptide effects may be mediated by non-chiral cell membrane interactions similar
to those of antimicrobial peptides. [9] However, there is now new evidence that C-peptide binds to specific cell
surface receptors which has been obtained using fluorescence correlation spectroscopy. Specific binding of
human C-peptide could be demonstrated for human tubular cells, skin fibroblasts and saphenous venous
endothelial cell. [11 Kas for C-peptide binding was 3.10-9 M-1. Insulin, IGF and II, proinsulin and NPY
showed no cross-reactivity. The C-peptide binding isotherm’indicates that half saturation is reached at approxi-
mately 0.9nM. This finding explains the consistent observation that no effects of C-peptide can be observed in
healthy individuals or animals, in whom the ambient C-peptide concentration will be sufficient to cause satura-
tion of C-peptide receptors.
Reduced levels of endoneurial Na+, K+-ATPase and diminished blood flow have been reported in
diabetes. The effect of C-peptide on motor nerve conduction velocity [9] was observed in STZ-treated rats.
In addition, a significant improvement of autonomic nerve function, as evidenced by increased heart rate
variability during breathing, has been demonstrated in patients with type 1 diabetes and signs of autonomic .-. [111 neuroparny.
In conclusion, the available data establish that C-peptide is not as biologically inert as previously believed.
Instead, it now emerges as an active peptide hormone with potentially important physiological effects. The possi-
bility should be considered that C-peptide replacement together with insulin administration might be beneficial in
type I diabetes patients.
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Interaction and Dynamics of C-peptide and Cell Surface Bound Receptors
RUDOLF RIGLERa, ALADDIN PRAMANIKa, KARIN EKBERGb, BO LENNART JOHANSSONb,
HANS JORNVALL and JOHNWAHRENb
aDepartments ofBiochemistry and Biophysics, bClinical Physiology,
Karolinska Institutet, S-17177 Stockholm, Sweden
The development of single molecule detection and fluorescence correlation spectroscopy (FCS) [1] has provided
the tools to analyze the interaction between fluorescently tagged ligands and their specific targets. We have been
able to show that tetramethylrhodamin labelled C-peptide is able to bind specifically to receptors at the cell
membrane. From, the study of the Brownian motion of C-peptide receptor complexes we were able to show [2,31
(i) a high affinity binding of the C-peptide to the receptor, (ii) a high specificity of the interaction which is related
to a C-terminal pentapeptide sequence. Furthermore the data obtained from studies where the function of G-pro-
teins was inhibited by pertussis toxin and a significant change of the binding affinity was found, suggest the
existence of an allosteric network involving receptor conformations with different affinities to both C-peptide as
well as G-protein.
Recent developments of 3 dimensional imaging of the C-peptide receptor complex in living cells and the
simultaneous analysis of the Brownian mobility provides new insights in the functional activity of the C-peptide.
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Conservation and Variability: C-peptide Versus Other Biopeptides
HANS JORNVALL and ERIK NORDLING
Department ofMedical Biochemistry and Biophysics, Karolinska Institutet, SE-17177 Stockholm, Sweden
Observations of clinical effects Of C-peptide in patients with diabetes type I,[1] combined with measurable effects
of C-peptide and its fragments on cellular Na+K+ ATPase activity, [2, 31 and of direct cellular binding interactions
of C-peptide, [41 have triggered interest in C-peptide and its possible role as a biologically active hormone. Still,
decisive break-throughs in definitions of receptor(s) have not been reported, and contradictory reports still exist
h -[561 regarding which segments of C-peptide that may be important, or through wh’c mechanisms (cf. ). For these
reasons, it is of interest to study the chemical variability of C-peptide as deduced from its molecular evolution
and to compare that with the species variability of conventional peptide hormones. Notably, C-peptide is now
known in PIR databank entries for no less than 37 vertebrate species, and insulin for 72 species. We have correlat-
ed the patterns for these peptides with those for vasoactive intestinal polypeptide (VIP, forms from 17 species),
secretin (9 forms), glucagon (31 forms), insulin-like growth-factor I (IGF1, 23 forms), IGF2 (26 forms), gastrin (14
forms), gastrin releasing peptide (GRP, 10 forms), parathormone (15 forms), substance P (20 forms), cholecys-
tokinin (CCK, 20 forms), somatostatin (28 forms), gastric inhibitory polypeptide (GIP, 5 forms) and pancreatic
polypeptide (24 forms). Several observations are apparent from this set of 15 different bioactive peptides.
First of all, C-peptide is the peptide with the largest species variability. Its pattern is markedly different from
those for both insulin and IGFs. Of course, this C-peptide variability is a concern in relation to a specific function
of C-peptide, since conventional peptide hormones usually have some segment with species conservation, consti-
tuting an active site in receptor binding interactions. In short, observations on the now large set of species variants
do not immediately define a biologically active segment for C-peptide.
Second, the conservation patterns of all the 15 biopeptides fall into four groups of different variability, with C-pep-
tide in the most variable group, but within that group not that enormously more variable than its fellow peptides in
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the same group (GRP and parathormone). Hence, from an evolutionary point of view, based on observations of the
species variability pattern, the case for C-peptide as a hormone is still, in spite of its variability, open for considera-
tion. Of the 15 biopeptides in the four sub-groups, remaining peptides, in the order of decreasing variability, are a
group of moderately variable peptides (CCK, secretin, pancreatic polypeptide and gastrin); a group of more con-
served peptides (GIP, insulin, IGF1 and IGF2); and a group of highly conserved, or close to "mammalian-constant"
peptides (somatostatin-14, glucagon, VIP and substance P). Hence, spread is quite extensive among the 15 peptides.
Third, even within a well defined and fully established peptide family, like the glucagon family (with
glucagon, VIP and secretin, among the present examples) spread is extensive. Although strictly homologous,
these hormones fall in separate sub-groups (more constant glucagon and VIP versus more variable secretin) and
differ about 4-fold or more in variability, i.e., evolutionary speed. Consequently, considerable structural differ-
ences and conservation differences are allowed in a single peptide family.
Fourth, and perhaps most important, even with its variability, C-peptide does show some conserved sequence
patterns. One such pattern concerns single residues along the molecule, where five non-consecutive positions
stand out. If they are to form a receptor binding site, that site is either non-continuous, or, if continuous, inter-
vening variable residues must co-vary with corresponding variability in the receptor(s). Neither of these patterns
is typical for ligand-receptor interactions within the hormone field.
However, binding through a few critical, single-residue hits and intervening residue variability occurs in pep-
tide interactions with the major histocompatibility molecules (MHC of classes and III7’81). Hence, if C-peptide
participates in receptor interactions, the binding sites may perhaps be of the critical type like in MHC binding
pockets rather than of continuous residue type like in many traditional peptide hormones. These findings have
implications for the search regarding themode of binding interactions in which C-peptide may participate with its
putative receptor(s). Whether this pattern reflects complex interactions for C-peptide, perhaps also with associated
cellular interactions involved, remains to be elucidated. In any event, the C-peptide pattern still deviates from ran-
dom chance variations and may, in spite of its variability, give hope of finding putative C-peptide receptor(s), in
which case their untraditional patterns may explain difficulties thus far at receptor definitions.
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Molecular Basis for the Insulinomimetic Effects of C-peptide
GEORGE GRUNBERGER, XIAOLING QIANG, ZHEN-GUO LI, SURESH T. MATHEWS,
DIEGO SBRISSA, ASSIA SHISHEVA and ANDERS A. F. SIMA
Centerfor Molecular Medicine and Genetics, Department ofInternal Medicine, Department ofPathology,
Department ofNeurology, Department ofPhysiology, Morris Hood Jr. Comprehensive Diabetes Center,
Wayne State University School ofMedicine, Detroit, Michigan
C-peptide, released by the ]3-cells of pancreatic islets, elicits salutary physiological responses in patients with
type 1 diabetes mellitus. We show that synthetic rat C-peptide stimulates several insulin-like cellular effects in a
rat skeletal muscle cell system. To elucidate the molecular mechanisms(s) underpinning such insulinomimetic
actions as glycogen synthesis and amino acid uptake, we investigated effects of C-peptide on several elements of
the insulin signaling pathway. In rat L6 cells, physiological concentrations of C-peptide (0.3-3nM) activated
insulin receptor tyrosine kinase, IRS-1 tyrosine phosphorylation, PI 3-kinase activity, MAPK phosphorylation,
p90Rsk, and GSK3phosphorylation. C-peptide-dependent effects were not reproduced by a scrambled C-peptide
sequence. Only submaximal insulin concentrations (up to 10 nM) combined with submaximal C-peptide
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concentrations led to additive effects. Addition of C-peptide to the maximally stimulatory insulin level (100 nM)
did not increase the effect of insulin, strengthening the conclusion that same signaling elements are used by both
of these ligands. However, differences in specific segments of the signaling pathway (e.g., lack of Akt activation
by C-peptide and the bell-shaped dose response to C-peptide) indicate that C-peptide elicits some effects by a
mechanism distinct from that of insulin. We speculate that C-peptide could modulate metabolic effects of insulin
by enhancing them at low hormone concentrations and dampening them at high hormone levels.
The Effect of C-Peptide on Vascular Tonicity
T. FORST
Dept. Internal Medicine and Endocrinology, University Mainz, Mainz, Germany
Numerous functional and structural microvascular disturbances have been reported for patients suffering from
type 1 diabetes. Microvascular blood flow is regulated by endothelial cell function, the autonomic nervous
function, rheologic properties and a couple of metabolic factors.
In patients suffering from diabetes mellitus type 1, skin microvascular blood flow is disturbed early in the
cause of the disease with a maldistribution of nutritive and subpapillary blood flow. We investigated the
influence of C-peptide administration on skin blood flow in type I diabetic patients and healthy control subjects
by the use of laserdopplerfluxmetry and intravital capillary microscopy. In type 1 diabetic patients nutritive
capillary blood flow was reduced by about 13% compared with the healthy control group. Replacement of
human C-peptide completely restored nutritive capillary blood flow in these type 1 diabetic patients, while no
effect was seen in the healthy control group. A linear relationship was found between plasma C-peptide levels
and the capillary blood flow velocity (r 0.401; p < 0.0001). No impact of C-peptide could be observed on sub-
papillary blood flow measured by laserdopplerfluxmetry. In addition, spectral analysis of flow motion revealed
no significant influence of C-Peptide on neurovascular control.
There is some evidence that C-peptide action in microvascular blood flow is mediated by endothelial release
of NO (see abstract of T. Kunt). Therefore, we measured plasma cGMP.levels, as a parameter of endothelial NO-
secretion in type I diabetic patients following C-peptide administration. There was found 23% increase in plasma
cGMP levels after substituation of human C-peptide infusion in type I diabetic patients confirming the assump-
tion of a NO mediated vascular effect of C-Peptide.
Na+K+ ATPase is involved in the regulation of microvascular blood flow and is well known to be reduced in
diabetes mellitus. In our investigations, C-Peptide supplementation in type 1 diabetic patients has shown to
increase erythrocyte Na+K+ ATPase activity by about 100%. There was found a linear relationship between
plasma C-peptide levels and erythrocyte Na+K+ ATPase activity (r 0.46; p < 0.01). Therefore, restoration of
Na+K+ ATPase activity may further affect microvascular blood flow by influencing vascular tonicity or erythro-
cyte flexibility and blood rheology.
In conclusion, C-Peptide affects microvascular blood flow by different mechanisms leading to an increase in nutri-
tive capillary blood flow relatively to thermoregulatory or arteriovenous shunt flow. These findings might explain
the beneficial effects of C-Peptide supplementation on microvascular complications in diabetes mellitus type 1.
C-peptide and Blood Flow Regulation in Type 1 Diabetes
KARIN EKBERG
Dept. of Surgical Sciences, Section of Clinical Physiology, Karolinska Institute, Stockholm, Sweden
One of the early findings of C-peptide’s effect in type I diabetes was its ability to reduce the glomerular filtration
rate, increase renal blood flow and reduce the renal filtration fraction. Ill It was hypothesized that C-peptide may
cause a reduction in capillary leakage, possibly by an increase in capillary recruitment. It had b,een described pre-
viously that diabetic patients have an increased vascular permeability. [2] To examine C-peptide s possible effect on
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vascular permeability, IDDM patients were studied during rhythmic forearm exercise.TM It was found that both
forearm blood flow and capillary diffusion capacity (CDC) increased during C-peptide replacement (+ 27 + 4%,
p < 0.001 and 52 9%, p < 0.01, respectively) and vascular resistance decreased to levels similar to those found in
healthy control subjects. The technique used did not allow a conclusion as to whether CDC was increased due to
altered capillary recruitment and/or permeability. It was shown in a subsequent study using the perfused rat
hindquarter model that C-peptide has no effect on vascular permeability but stimulates capillary recruitment. [41
C-peptide exerts a stimulatory effect on forearm blood flow also in the resting state. In a recent study in Stockholm
the concentration-dependent effect of C-peptide on forearm blood flow was examined in 12 IDDM patients in a
placebo-controlled, double-blind study using venous occlusion plethysmography, a technique for the measurement
of total blood flow in a forearm segment. It could be demonstrated that a low dose of C-peptide (1 pmol/kg/min)
resulting in a plasma C-peptide level of ---0.2 nM significantly increased forearm blood flow with 15% above basal.
When the C-peptide concentration was increased to ---1 nM by a higher infusion rate (5 pmol/kg/min, the dose pre-
viously used in all of the above studies) blood flow was increased by 25%. However, with an even higher dose (25
pmol/kg/min) resulting in a C-peptide concentration of ---7 nM, a significantly higher blood flow was not found.
This was in accordance with previous findings by Johansson and Pernow 1999 [sl where basal forearm blood flow
was stimulated by C-peptide (5 pmol/kg/min) in IDDM patients (+25 6%, p < 0.01). In that study it was also con-
firmed that increased blood flow was associated with a decreased vascular resistance (-17 + 5%, p < 0.01).
To examine C-peptide’s effect on endothelial function of the larger arteries in type 1 diabetes, Johansson and
colleagues [61 determined blood flow velocity and brachial artery diameter responses following reactive hyper-
emia (RH) and administration of glyceryl trinitrate (GTN) using high-resolution ultrasound technology. They
found that the shear stress induced arterial dilatation following RH was impaired in the diabetes patients (dia-
betics 2% vs. controls 9%), whereas the response to GTN was normal. Following C-peptide administration the
basal blood flow velocity in the brachial artery was increased by 26%, p < 0.05, but the responses to RH and GTN
were unaltered. This suggests that C-peptide acts primarily on resistance arterial vessels.
As to the mechanism for C-peptide action on blood flow, it has been demonstrated in bovine aortic endothelial
cells that C-peptide stimulates on the endothelial nitric oxide synthase (eNOS) activity, resulting in an increased
NO production. [71 The C-peptide induced NO release was abolished by addition of a NOS inhibitor. Recently,
this was also tested in humans; intra-arterial administration of C-peptide to type 1 diabetes patients resulted in
an immediate blood flow response (---30%) and when C-peptide was co-administered with L-NMMA (a NOS
inhibitor) the stimulatory effect of C-peptide was abolished. [8]
In conclusion, the available data indicate that in type I diabetes C-peptide stimulates eNOS and release ofNO
primarily at the level of the resistance vessels, resulting in ihcreased blood flow, decreased vascular resistance
and increased capillary recruitment. C-peptide’s effect is concentration-dependent in the range of 0-1 nM. The
stimulatory effect of C-peptide may be beneficial in the prevention of diabetic complications.
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The Pathogenetic Role of C-peptide Deficiency in Type 1 Diabetic Neuropathy
ANDERS A. F. SIMA
Wayne State University, Detroit,ML USA
C-peptide has an insulin-like effect and ameliorates the acute nerve conduction defect (NCD) in experimental
and human type I diabetic neuropathy (DN). In this study diabetic BB/Wor-rats were treated with rat C-peptide
(75ng/kg) from onset of diabetes for 8 months (prevention-group (PG)). In a separate experiment 5 mo untreated
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diabetic BB/Wor-rats were started on the same C-peptide treatment continued to 8 mo of diabetes (intervention
group (IG)). In the PG the NCD was significantly decreased (p < 0.001) compared to untreated BB/Wor-rats and
was similar to that of normo-C-peptidemic and isohyperglycemic type 2 BBZ rats. This effect was associated with
significant preventions of nodal changes (p < 0.001) including axo-glial dysjunction (p < 0.001), which was not
different from non-diabetic control rats. Axonal atrophy and Wallerian degeneration were significantly prevent-
ed (both p < 0.05). In the IG the NCD decreased significantly (p < 0.01) during the 3 mo treatment period. Associ-
ated with the functional improvement, nodal changes improved significantly (p<0.001) as did axonal
degenerative changes (p < 0.01). C-peptide treatment in the IG resulted in a significant increase in the frequency
of regenerating fibers (p < 0.001) compared with untreated 5 mo diabetic rats. These studies demonstrate that C-
peptide replacement in type 1 diabetes significantly prevents the chronic NCD and structural changes. Further-
more, C-peptide treatment significantly improves already established chronic functional and structural
abnormalities in DN. This is the first demonstration of a therapeutic improvement of established neuropathy in
experimental diabetes. We conclude that C-peptide deficiency in type 1 diabetes is an important pathogenetic
component inDN and that its replacement may provide a valuable adjunct to intensive insulin treatment.
Neuroprotective Effect of C-peptide: In Vivo and In Vitro Studies
ZHEN-GUO LI, WEIXIAN ZHANG, GEORGE GRUNBERGER and ANDERS A. F. SIMA
Centerfor Molecular Medicine and Genetics, Morris Hood Jr. Diabetes Center, Dept. ofPathology,
Internal Medicine, Neurology, Wayne State University, Detroit Michigan
It is known that IGF plays an important neuroprotective effect in both in vivo mid in vitro studies. We have previ-
ously shown that the IGF system is perturbed in CNS of type-I spontaneously diabetic BB/W-rats, and is associ-
ated with programmed cell death in hippocampus mid frontal cortex. In this study, we provide evidence
showing that C-peptide plays a neuroprotective role by preventing the perturbed IGF system in the CNS of
BB/W-rats. By using Northern blot hybridization, IGF-I, II, IGF-I receptor (IGF-IR) and insulin receptor (IR)
expressions were found to be decreased in CNS of diabetic BB/W-rats compared to the age-matched control ani-
mals. In diabetic rats supplemented with 75 ng/kg/day C-peptide from onset of diabetes, the impaired mRNA
expression of IGF-I, II, IGF-IR and IR was partially prevented and hippocampal neuronal apoptosis was prevent-
ed as assayed by LM-PCR assay and TUNEL staining. To elucidate the mechanism(s) underlying C-peptide’s
action, we examined signaling pathway of C-peptide in human neuroblastoma SH-SY5Y cells. Under 300 mM
glucose, SH-SY5Y cells undergo apoptosis as shown with TUNEL/DAPI stainings. When C-peptide (10 nM) was
added to the high glucose medium, the proportion of apoptotic cells are reduced compared with those without
C-peptide treatment. C-peptide, in the presence of insulin, substantially increased p38 phosphorylation and sig-
nificantly decreased JNK phosphorylation, indicating a bi-directional regulation of these two stress-induced
MAP kinases involved in the IGF-IR mediated anti-apoptotic pathway. These data therefore suggest that the anti-
apoptotic effect of C-peptide may be mediated by enhancing the activity of IGF-IR/IR signaling pathway.
Effects of C-peptide in Experimental and Clinical Nephropathy
BO-LENNART JOHANSSON
Section of Clinical Physiology, Department of Surgical Sciences, Karolinska Hospital,
SE 171 76 Stockholm, Sweden
An elevated glomerular filtration rate (GFR) and glomerular hypertrophy are frequent findings in the early stage
of type 1 diabetic nephropathy. Insulin therapy decreases glomerular hyperfiltration but not to normal levels of
GFR. C-peptide levels are low or unmeasurable in type 1 diabetes and this peptide is primarily catabolized by
the kidneys. These considerations prompted us to examine the possible influence of C-peptide on renal function
in streptocotozin (STZ) diabetic rats.
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Short-term infusion (140 min) of C-peptide in STZ-treated animals was found to diminish GFR, reduce renal
protein leakage and augment the renal functional reserve. [1] Subsequent studies involving C-peptide infusion for
14 days in rats with experimental diabetes not only confirmed the results with regard to reduction in GFR and
diminished albumin excretion but also demonstrated markedly reduced renal structural changes, as evidenced
by reduced glomerular hypertrophy. [21
The above results in diabetic animals have been borne out in studies involving patients with type I diabetes and
mild diabetic nephropathy. Thus, i.v., infusion of human C-peptide (2 h) was found to be accompanied by a signifi-
cant reduction of GFR (7%) and a small rise in renal blood flow (3%). [3] During more prolonged C-peptide adminis-
tration (4 weeks) in type 1 patients (n 9), provided by subcutaneous continuous rate infusion, it could be shown
that both GFR and urinary albumin excretion decreased significantly, indicating a beneficial effect on glomerular
permeability in type 1 diabetes. [4] However, in this study glycemic control tended to improve in the C-peptide
treated group but not in the controls. This raised the question of whether the observed improvement in renal func-
tion represented a direct C-peptide effect or if it was a secondary effect related to the amelioration of blood glucose
control. Therefore, a larger study was undertaken involving 22 type 1 diabetic patients with microalbuminuria
receiving human C-peptide in doses calculated to restore the physiological concentration for 3 months in a double-
blind randomized cross-over design. In this study glycemic control was not different during C-peptide and placebo
treatment, respectively. The results showed a statistically significant, substantial reduction in microalbuminuria
(40%) during C-peptide administration and no significant change during placebo treatment. [51
The mechanism underlying the diminished albumin excretion during C-peptide administration is not known.
It is possible, however, that C-peptide may exert a direct effect on the glomerular handling of albumin, as sug-
gested from the studies of renal function in streptozotocin induced diabetic rats. A blunted Na+, K+-ATPase
activity has been shown in animals and humans with diabetic mellitus, especially in renal and nerve tissue. It has
been found that C-peptide exerts a concentration dependent stimulatory effect on Na+, K+-ATPase activity in rat
renal tubular cells. Similar findings have also been obtained in glomeruli from streptozoto-cin-induced diabetic
rats. Finall,y evidence is now available, indicating that C-peptide may stimulate endothelial nitric oxide
synthase. [61 In this context it is of interest that specific binding of C-peptide to membrane-bound receptors has
[7] been demonstrated in the nanomolar concentration range for renal cells. Thus, it may be hypothesized that C-
peptide has the potential to influence membrane permeability and transport as well as stimulate regional blood
flow, possibly resulting in improvements in renal function in the diabetic state.
In conclusion, the combined animal experiment and human trial data demonstrate that C-peptide replacement
in type I diabetes and mild nephropathy exerts a beneficial effect on renal structure and function. The possibility
should be considered that C-peptide should be provided .to type 1 diabetes patients to prevent or retard the
development of diabetic nephropathy.
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Grbl0, a Potential Partner of P85 P13-Kinase in Insulin-Stimulated Metabolism
SUJOY BHATTACHARYA, YOUPING DENG, RAMASWAMY ORRE,
CHONG BAL andHOLMO RIEDEL
Department of Biological Sciences, Wayne State University, Detroit, MI
Growth factor receptor binding protein 10 (Grbl0) has been implicated as a signaling mediator in association
with several mitogelic peptide hormone receptors including the insulin receptor. In response to insulin Grbl0 is
specifically recruited into a complex with the insulin receptor. However, a role of Grbl0 in the regulation of
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insulin-stimulated metabolic responses has not been reported. In this study we have investigated the putative
role of one Grb10 variant in insulin-induced metabolism with several independent experimental approaches.
We found that over-expression of complete Grbl0 cDNA in Rat 1 fibroblasts over-expressing insulin receptors
or in Rat L6 myocytes stimulated insulin-induced cellular responses including glycogen, synthesis, glucose
uptake, amino acid uptake and lipogenesis consistent with a role of Grbl0 in insulin-induced metabolism. In
contrast, putatively dominant-negative cell membrane-permeable Grbl0 SH2 and Pro-rich domain fusion pep-
tides substantially inhibit insulin-stimulated glycogen synthesis which indicated a role of these domains in
insulin-regulated metabolism, consistent with a stimulatory role of complete Grbl0. Association of complete
Grbl0 with the regulatory subunit p85 of P13-kinase was observed in response to insulin stimulation. Both the
Grbl0 SH2 and Pro-rich regions inhibited the association between Grbrl0 and p85. Consistent with their impli-
cated roles in Grb10-p85 association, both the Grbl0 SH2 and Pro-rich regions substantially inhibited insulin-
stimulated P13-kinase activity, suggesting functional roles in P13-kinase activation. The observed association
between Grbl0 and p85 may be indirect and involve other signaling adapters. One candidate is Gabl which may
link Grbl0 to the MAP kinase pathway. In this context both the Grbl0 SH2 domain and the Pro-rich region were
found to inhibit MAP kinase activation by insulin. Over-expression of Grbl0 in PC12 neural cells stably express-
ing an inactive p85 P13-kinase restored insulin-induced glycogen synthesis. A possible interaction of the Grbl0
Pro-rich region with the SH3 domain of p85 could contribute to P13-kinase activation and the transduction of the
insulin-induced metabolic signal. When combined, our findings implicate Grbl0 as a potential partner of p85
P13-kinase with a role in signaling mechanisms that mediate insulin-stimulated metabolic responses.
C-peptide Inhibits Protein Tyrosine Phosphatase and Promotes Glycogen Synthesis
ZHEN-GUO LI, XIAOLING QIANG, SURESH MATHEWS,
ANDERS A. F. SIMA and GEORGE GRUNBERGER
Centerfor Molecular Medicine and Genetics, Morris Hood Jr. Comprehensive Diabetes Center,
Depts. ofInternal Medicine, Pathology, Neurology, Wayne State University, Detroit, Michigan
In spite of extensive investigation, the mechanism(s) mediating C-peptide’s beneficial effects on diabetic neuropa-
thy and nephropathy is (are) not clean We have demonstrated previously that C-peptide exerts insulino-mimetic
effects, such as activation of glycogen synthesis and amino acid uptake. Direct evidence that C-peptide binds to
the insulin receptor, however, has not been established. In this study, we demonstrate that C-peptide inhibits pro-
tein tyrosine phosphatase (PTP) activity in L6 myoblasts, in a dose-related manner. The maximal inhibitory effect
was shown in ranges of 0.3-3.0 nM equivalent to its physiological concentrations. As a result of the PTP inhibition,
insulin receptor autophosp-horylation and IRS-1 phosphorylation were enhanced. Consistent with these findings,
C-peptide at the above concentrations enhanced glycogen synthesis and potentiated the effect of insulin (10 nM)
in L6 myoblasts. These results indicate that C-peptide may either act via the insulin receptor directly or cross talk
with an activated cognate C-peptide receptor at a proximal level of the insulin-signaling pathway.
Molecular Pathology of the Node of Ranvier in Type I Diabetic Neuropathy:
A Role for Insulin and C-peptide Deficiencies?
CHRISTOPHER R. PIERSONa, WEIXIAN ZHANGa, YUICHI MURAKAWAa,
JOHN WAHRENb and ANDERS A. F. SIMAa
Wayne State University, Department ofPathology and Morris Hood Jr. Comprehensive Diabetes Center, Detroit, MI;
bDepartment of Surgical Sciences, Karolinska Hospital, Stockholm, Sweden
C-peptide replacement in type BB/W-rats prevents both the initial metabolic and the chronic structural
changes at the node of Ranvier. Nodal integrity depends on specialized molecules including ankyrinG
and caspr. AnkyrinG interacts with Na+ channels, Na+K+-ATPase, cell adhesion and axonal cytoskeletal
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molecules, sequestering them to the node of Ranvier. Caspr localizes to the septate-like junctions that form
between axons and myelin loops. These interactions are responsible for the regional specializations at the node
and permit the timely propagation of action potentials. The insulin receptor is localized to paranodal cell
membranes[1] and C-peptide potentiates the insulin signaling pathway,[21 suggesting that insulin signaling may
be critical to nodal molecule activity. In vitro studies have suggested a potential interaction between caspr and
[3] PI3K via SH3 domains. We hypothesize that the actwtes of these nodal molecules are altered in type neu-
ropathy and that insulin and/or C-peptide deficiencies may underlie these changes. Immunoblotting (sciatic
nerve) and semi-quantitative RT-PCR (DRG) reveal no difference in the expression levels of ankyrinG; and its
associated molecules (Na+ channels, Na+ K+-ATPase, L1, and NCAM) between control; C-peptide treated
(75ng/kg/d), and untreated diabetic BB/W-rats at 2 and 8 mo. of diabetes. AnkyrinG is post-translationally
modified at serine residues by O-linked N-acetylglucosamine (O-GlcNAc). Immunoprecipitation of
ankyrin[G] in SH-SY5Y cells treated with C-peptide (3.3nM), insulin (4.0nM), or both for 2 hr showed an
increase in O-GlcNAc modification of ankyrin[G], with insulin alone. Whereas cells exposed for 20 hr showed
decreased O-GlcNAc modification by insulin alone, which was enhanced when C-peptide was added. There-
fore, C-peptide may potentiate the effects of insulin long term (20hr) but blunt insulin’s effects short term
(2hr). Immunoblotting (sciatic nerve) and semi-quantitative RT-PCR (DRG) revealed no difference in the
expression level of caspr at 2 mo. however, at 8 mo. caspr protein expression was decreased in diabetics.
Immunohisto-chemical studies show that caspr is laterally displaced from the paranode in diabetic rats at 2
mo., an alteration that is partially rectified by C-peptide. These findings suggest that localization and post-
translational modifications may be more important than alterations in the expression of these nodal molecules
in type diabetic neuropathy.
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C-peptide Signaling-is it Mediated Through Insulin Receptor?
XIAOLING QIANG, SURESH T. MATHEWS, ZHEN-GUO LI, ANDERS A. E SIMA
and GEORGE GRUNBERGER
Centerfor Molecular Medicine and Genetics, Department ofInternal Medicine, Department ofPathology,
Wayne State University School ofMedicine Detroit, Michigan 48201
Earlier we have shown that synthetic rat C-peptide stimulates several insulin-like cellular effects viz., glycogen
synthesis and amino acid uptake, in a rat L6 skeletal muscle cells. Binding of insulin to its receptor results in acti-
vation of insulin receptor tyrosine kinase (IR-TK), followed by phosphorylation of intracellular substrates, propa-
gating receptor signals throughout the cell. Our goal was to verify if C-peptide activated proximal steps of the
insulin signal transduction pathway. We demonstrate that physiological concentrations of C-peptide (0.3-3 nM)
activated IR autophosphorylation, TK, and IRS-1 tyrosine phosphorylation in a dose-dependent manner in rat L6
cells, indicating that C-peptide mimics insulin’s effects of IR activation. To understand the mechanism of C-
peptide-induced IR activation, binding studies were performed. In L6 cells, unlabeled C-peptide displaced
bound [125I] C-peptide in a whole cell competitive binding assay, suggesting the existence of C-peptide receptors.
Further, physiological concentrations of unlabeled C-peptide displaced [125I]-insulin, bound to wheat
germ agglutinin-purified IR. Could our results suggest that C-peptide’s insulinomimetic effects are mediated via
binding of C-peptide to IR?
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IGF-I Inhibits High Glucose Induced Oxidative Stress and Mitochondrial
Dysfunction in a Model of Diabetic Neuropathy
J. w. RUSSELL, D. GOLOVOY, P. MAHENDRU and E. L. FELDMAN
Department ofNeurology, University ofMichigan, Ann Arbor, M148109
In streptozotocin diabetic rats hyperglycemia is associated with apoptotic changes in dorsal root ganglion neu-
rons such as DNA fragmentation and disruption of mitochondria (Mt). These events are associated with loss of
sensory neurons and clinical neuropathy. We find that hyperglycemic induced Mt dysfunction is a critical precur-
sor for neuronal apoptosis. Using confocal microscopy of cultured dorsal root ganglion neurons exposed to 20
mM glucose in serum/insulin free defined medium, there is a rise in H2DCFDA levels (a measure of reactive
oxygen species [ROS]), that peaks at 6 h, followed by a decline in ROS corresponding to an increase in neuronal
apoptosis over the following 72 h. The rise in ROS is coupled with a five fold increase in Mt size corresponding
to Mt swelling and release of cytochrome-c into the neuronal cytosol, events that are p recursors to apoptosis.
The rise in ROS and swelling of Mt is inhibited by 3M myxothiazole, which blocks Mt superoxide generation,
as well as by 50-100M bongkrekic acid (BKA) which blocks the ANT/VDAC complex of the Mt and prevents
depolarization of the Mt membrane, Insulin-like growth factor-I (IGF-I) mimics the anti-oxidant properties of
myxothiazole and the Mt membrane stabilizing effect of BKA. IGF-I inhibits Mt enlargement and depolarization
(p < 0.01), and cytochrome-c release from the Mt. These results indicate that an early glucose induced rise in ROS
is associated with Mt swelling in vitro, and can be blocked by anti-oxidants and IGF-I. These findings support the
growing evidence of increased oxidative stress in diabetic neuropathy and indicate that JGF-I can stabilize neu-
ronal Mt and reduce oxidative processes leading to neuronal dysfunction. This work was supported by NIH
NS01938, VA Merit and Juvenile Diabetes Foundation International (JWR); NIH NS32843, Juvenile Diabetes
Foundation International and the American Diabetes Association (ELF).
IGF-I Inhibits Programmed Cell Dea-ttl Associated
with High Glucose Induced Oxidative Stress
J. W. RUSSELL, D. GOLOVOY, A. R. BERENT and E. L. FELDMAN
Department ofNeurology, University ofMiChigan, Ann Arbor, M148109
In previous studies, we have shown that hyperglycemia induces mitochondrial (Mt) enlargement and disruption
in streptozotocin treated diabetic rats. Furthermore, these changes are associated with histological evidence of
DNA fragmentation and cell death. The role of hyperglycemia in inducing Mt dysfunction and apoptosis was
further characterized in vitro using dorsal root ganglion (DRG) cultures. In the presence of 20mM added glucose
there is a 40% increase in caspase-3 cleavage measured using the CM antibody (gift from Dr. A. Srinivasan,
IDUN Pharm, La Jolla, CA) at 6 h and 55% at 24 h (p < 0.001). Myxothiazole (3 M), an inhibitor of Mt oxidation,
blocks release of cytochrome-c from the intermitochondrial space into the cytosol, and inhibits cleavage of cas-
pase-3 up to 24 h. Furthermore, 50-100M bongkrekic acid (BKA) which blocks the ANT/VDAC complex of
the Mt and prevents depolarization of the Mt membrane, inhibits caspase-3 cleavage up to 24 h (p <: 0.001).
Apoptosis,.induced by 20 mM added glucose, as measured by the percent of TUNEL positive neurons, is blocked
by addition of the pan caspase inhibitor Boc-Asp-FMK and IGF-I. Thus in vitro, PCD associated with glucose
induced oxidative stress or Mt depolarization, can be blocked by anti-oxidants, Mt stabilizing agents and IGF-I.
These findings support the association between oxidative stress and PCD in models of diabetic neuropathy. This
work was supported by NIH NS01938, VA Merit and Juvenile Diabetes Foundation International (JWR); NIH
NS32843, Juvenile Diabetes Foundation International and the American Diabetes Association (ELF).
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Specific Regulation by Ras of Cytokine-Mediated Nitric Oxide
Generation in the Pancreatic//Cell
MARIE TANNOUSa, MICHAEL POPOFFb and ANJAN KOWLURU
aDepartment ofPharmaceutical Sciences, Wayne State University and John D. Dingell VA Medical Center,
Detroit, M148201. USA; bUnit ofMicrobial Toxins, Pasteur Institute, 25 Rue Docteur Roux, 75724 Paris, Cedex 15, France
Insulin-dependent diabetes mellitus develops as a consequence of the selective destruction of insulin producing/3
cells due to autoimmune aggression. It has been shown that such cytotoxic effects are mediated by cytokines [e.g.,
interleukin-l]3] secreted by the infiltrating immune cells. Cytokine-induced islet/3 cell death is attributed primari-
ly to the induction of nitric oxide synthase [iNOS] leading to the generation of nitric oxide [NO] within the cell,
which in turn, culminates in cell death by apoptosis and nerosis. In the present study, we have shown that expo-
sure of insulin secreting ]3 [HIT-T15] cells to interleukin-1/3 [IL-113] results in a time- and dose-dependent increase
inNO release. Such effects by IL-1]3 on NO release were mediated by induction of iNOS from these cells. Preincu-
bation of HIT-T15 cells with Clostridium sordelli lethal toxin- 82, which irreversibly glucosylates and inactivates low
molecular weight GTP-binding proteins, such as Ras, Rap, and Rac, but not Cdc42, completely abolished IL-113-
induced NO release from these cells. Pre-exposure of HIT-T15 cells to Clostridium sordelli lethal toxin-9048, which
monoglucosylates and inhibits Ras, Cdc42, Rac, but not Rap also attenuated IL-1]3-mediated NO release. These
data indicate that activation of Ras and/or Rac may be necessary for IL-1/3-mediated NO release. Further, two
structurally dissimilar inhibitors of Ras function, namely manumycinA and damnacanthal inhibited, in a concen-
tration-dependent manner, the IL-113-mediated NO release from these cells. Together, our data provide evidence,
for the first time, that Ras activation is an obligatory step in IL-1]3-mediated NO release [presumably] subsequent
dysfunction of the pancreatic ]3 cell. It is likely that activation of other G-proteins [e.g., Rac] is downstream to the
site of regulation by Ras. These studies provide basis for future investigations to understand the mechanism of
cytokine-induced/3 cell death leading to the onset of insulin-dependent diabetes mellitus.
Hoechst 33342 Induces Apoptosis and Alters Insulin and Nitric Oxide
Release in Syrian Hamster Bets Cells
XINBO ZHANGa, ALISON LONGa, J. DOUGLAS FERRYa, VIKTOR BROVKOVYCHb,
TADEUSZ MALINSKIb and FREDERICK L. KIECHLE
aDepartment of Clinical Pathology, William Beaumont Hospital, Royal Oak M1;
bCenterfor Biomedical Research, Oakland University, Rochester, MI
Hoechst 33342 (H342), but not Hoechst 33258 (H258), induces apoptosis and inhibits topoisomerase I in a variety
of cell lines. To investigate the effect of H342 and H258 on Syrian hamster beta cells (HIT-T15), cell viability was
detected by trypan blue exclusion and DNA fragmentation by 1.5% agarose gel electrophoresis. After H342 or
H258 treatment, insulin release (measured in media) and intracellular insulin levels (measured in cell lysate)
were determined by a solid phase, competitive immunoassay (Coat-A-Count(R), Diagnostic Products Corp). Nitric
oxide release was measured using an electrochemical porphyrinic microsensor. Cell death and DNA fragmenta-
tion into multiples of 180-200 base pairs were both increased in a time-dependent manner after treatment with a
lethal dose (26.7mol/L H342) for 6-24 hours when compared with the control group, H258-treated cells or sub-
lethal dose (4.5/mol/L) of H342. Insulin release was increased by 0.5 fold after treatment with the lethal dose of
H342 for 1 hour and then decreased by 1.8 fold after 6 hours when compared with the control group, sublethal
dose or H258 group (4.5 or 26.7 mol/L). However, both intracellular and total insulin levels measured in the
cell lysates of Syrian hamster beta cells were significantly decreased in the presence of the lethal dose of H342 for
1 hour and 3 hours, respectively. H258 did not alter the insulin concentration compared to the control. Maximal
increase in nitric oxide (NO) release was 120% (4.5 mol/L H342) at 3 hours; 89% (26.7 mol/L H342) at 2 hours.
H258 did not alter NO release. These findings are consistent with the activation of proteases which degrade
intracellular proteins (insulin) and genomic DNA by protease-activated nuclease during H342-induced apopto-
sis. The relationship between NO production and insulin degradation requires further investigation.
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The Effect of C-peptide on Nitric Oxide
THOMAS KUNT
Dept. of. Endocrinology, University ofMainz, Mainz, Germany, Institutefor Clinical Research
and Development, Mainz, Germany, Hospital ofAnnweiler, Germany
There is increasing evidence for biological functions of human C-peptide. Recently, we have described that
proinsulin C-peptide increases nutritive capillary blood flow in type diabetes patients, whereas it has no such
effect in non-diabetic subjects. The aim of the presented studies was to elucidate cellular mechanisms of this
vasodilator effect in vitro by measuring the nitric oxide (NO) mediated increase of cGMP production in a RFL-6
reporter cell assay, by demonstrating endothelial calcium influx with the Fluo-3 technique and by demonstrating
the effect of C-peptide on erythrocyte deformability. C-peptide increased the release of NO from bovine aortic
endothelial cells (BAEC) in a concentration- and time-dependent manner. At physiological C-peptide concentra-
tions, endothelial NO production was approximately doubled (192 + 15% vs. control; p < 0.01). The NO release
G 2+ was abolished by the inhibitor of NO synthase N -nitro-L-arginine or when Ca was removed from the medi-
um superfusing the BAEC. C-peptide stimulated the influx of Ca2+ into the BAEC as demonstrated by the Fluo-3
technique. C-peptide did not change NOS III mRNA levels after 1, 6 or 24 h. These data indicate that C-pep_tide is
likely to stimulate the activity of the Ca2+ -sensitive endothelial NO synthase by increasing the influx of Ca2+ into
endothelial cells. Furthermore, we were able to show that erythrocyte deformability is attenuated in normo-
glycemic type diabetic patents compared to non-diabetic control subjects. If C-peptide was added to the ery-
throcyte suspensions of type 1 diabetic patients, the deformability of the red blood cells increased to normal
levels that were not different from those of control subjects. This effect was abolished if ouabain, an antagonist of
Na/K-ATPase, was added, We suggest that these effects may contribute to the increase in skin and muscle blood
flow previously demonstrated in man in vivo and may be induced by a stimulation of calcium influx and an acti-
vation of Na/K-ATPase and nitric oxide synthase as well.
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